Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel

Revista Espanola de Medicina Nuclear e Imagen Molecular

Volumn 33, Issue 1, 2014, Pages 14-21

  García García Esquinas, Marta A ^a   Arrazola García, Juan ^a   García Sáenz, José A ^a   Furio Bacete V ^a   Fuentes Ferrer, Manuel E ^a   Ortega Candil, Aída ^a   Cabrera Martín, María N ^a   Carreras Delgado, José L ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; PET CT

Indexed keywords

DOCETAXEL; FLUORODEOXYGLUCOSE F 18; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; TAXOID;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; PET SCANNER; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; TREATMENT RESPONSE; YOUNG ADULT; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; MASTECTOMY; MULTIMODAL IMAGING; MULTIMODALITY CANCER THERAPY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SCINTISCANNING; SECONDARY; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COMBINED MODALITY THERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM STAGING; NEOPLASM, RESIDUAL; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TAXOIDS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 84892983260     PISSN: 2253654X     EISSN: 22538070     Source Type: Journal    
DOI: 10.1016/j.remn.2013.04.008     Document Type: Article

References (23)

1. Ferlay J., Shin H.-R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20560135 [cited 5.11.2011].
2. Untch M., Fasching P., Konecny G., Hasmueller S., Lebeau A., Kreienberg R., et al. Abstract P1-11-03: pathological complete response after neoadjuvant chemotherapy+trastuzumab treatment predicts survival and detects a patient subgroup at high need for improvement of anti-hER2 therapy. Three year median follow-up data of the TECHNO trial. Cancer Res 2011, 70(24 Suppl.). P1-11-03-P1-11-03.
3. Partridge S.C., Gibbs J.E., Lu Y., Esserman L.J., Sudilovsky D., Hylton N.M. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. Am J Roentgenol 2002, 179:1193-1199.
4. Straver M.E., Aukema T.S., Olmos R.A.V., Rutgers E.J.T., Gilhuijs K.G.A., Schot M.E., et al. Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients. Eur J Nucl Med Mol Imaging 2010, 37:1069-1076.
5. Sataloff D.M., Mason B.A., Prestipino A.J., Seinige U.L., Lieber C.P., Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995, 180:297-306.
6. Feldman L.D., Hortobagyi G.N., Buzdar A.U., Ames F.C., Blumenschein G.R. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986, 46:2578-2581.
7. Avril N., Sassen S., Roylance R. Response to therapy in breast cancer. J Nucl Med 2009, 50(Suppl_1 May 1):55S-63S.
8. Symmans W.F., Peintinger F., Hatzis C., Rajan R., Kuerer H., Valero V., et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007, 25:4414-4422.
9. Choi J.H., Lim H.I., Lee S.K., Kim W.W., Kim S.M., Cho E., et al. The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: comparison with ultrasonography and magnetic resonance imaging. J Surg Oncol 2009, 102:392-397.
10. 18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy. Ann Surg Oncol 2009, 17:247-253.
11. Schneider-Kolsky M.E., Hart S., Fox J., Midolo P., Stuckey J., Hofman M., et al. The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET. Breast Cancer Res 2010, 12. R37-R37.
12. Wahl R.L., Jacene H., Kasamon Y., Lodge M.A. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009, 50(Apr 29):122S-150S.
13. NCCN Clinical Practice Guidelines in oncology: breast cancer. Version 2 2011, Available at: www.NCCN.com.
14. 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancerα A meta-analysis. Breast Cancer Res Treatment 2011, [Internet]. Available from: http://www.springerlink.com/index/10.1007/s10549-011-1780-z [cited 7.12.2011].
15. 18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2007, 34:1915-1924.
16. 18F-fluorodeoxyglucose positron emission tomography. Acta Radiol 2011, 52:21-28.
17. Hodgson N.C., Gulenchyn K.Y. Is there a role for positron emission tomography in breast cancer stagingα. J Clin Oncol 2008, 26:712-720.
18. Buchbender C., Kuemmel S., Hoffmann O., Stahl A.R., Kimmig R., Otterbach F., et al. FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results. Acta Radiol 2012, 53:628-636.
19. Sinn H.P., Schmid H., Junkermann H., Huober J., Leppien G., Kaufmann, et al. Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy. Geburtshilfe Frauenheilkd 1994, 54:552-558.
20. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. Acta Radiol 2012, 53:615-627.
21. 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging 2009, 36:1551-1557.
22. 18F-FDG PET/CT and apoptosis induced by neoadjuvant chemotherapy in breast cancer. Cancer Biol Ther 2007, 6:1442-1448.
23. Prati R., Minami C.A., Gornbein J.A., Debruhl N., Chung D., Chang H.R. Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy. Cancer 2009, 115:1194-1202.